Sign In
Buy RXST
$6.01
-0.0700 (-1.15%)
At Close: Jul 31, 2026
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
11:02am, Wednesday, 29'th Jul 2026
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
04:00pm, Sunday, 26'th Jul 2026
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 share
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
04:51am, Friday, 17'th Jul 2026
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
04:15pm, Wednesday, 15'th Jul 2026
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
10:40am, Monday, 13'th Jul 2026
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
10:02pm, Friday, 10'th Jul 2026
RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with m
RxSight: After Dropping To The Bottom, It's Time To Pick It Up
02:20pm, Friday, 10'th Jul 2026
RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
02:00pm, Friday, 10'th Jul 2026
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it is investigating potential claims agains
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
01:55pm, Friday, 10'th Jul 2026
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of director
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
12:00pm, Wednesday, 08'th Jul 2026
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASD
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
03:05pm, Tuesday, 07'th Jul 2026
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) con
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
10:32am, Tuesday, 07'th Jul 2026
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone pr
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
04:15pm, Monday, 06'th Jul 2026
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
03:02pm, Thursday, 02'nd Jul 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
